VIA
IOVA icon

Virtus Investment Advisers’s Iovance Biotherapeutics IOVA Stock Holding History

Virtus Investment Advisers’s Portfolio IOVA Stock Details IOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.19M Sell
285,020
-98,743
-26% -$375K 0.28% 182
2026
Q1 		$1.35M Buy
383,763
+73,122
+24% +$234K 0.37% 128
2025
Q4 		$848K Buy
310,641
+118,263
+61% +$274K 0.23% 138
2025
Q3 		$417K Hold
192,378
– – 0.12% 225
2025
Q2 		$331K Buy
192,378
+147,271
+326% +$366K 0.11% 236
2025
Q1 		$150K Buy
+45,107
New +$233K 0.04% 330

Other funds holding IOVA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
MFM
MHR Fund Management New York $1.92B AUM 119.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return

Virtus Investment Advisers's IOVA Position: Q2 2026 in Review

Virtus Investment Advisers reduced its Iovance Biotherapeutics (IOVA) stake by 26% in Q2 2026, selling an estimated $375K and leaving 285,020 shares worth $1.19M. The position accounts for 0.28% of the portfolio, ranked #182.

Virtus Investment Advisers first reported a position in IOVA in Q1 2025 and has held it in 6 quarters since. The position peaked at $1.35M in Q1 2026. 292 funds tracked by Wall St. Rank hold IOVA as of Q2 2026.

  • Virtus Investment Advisers held 285,020 shares of Iovance Biotherapeutics worth $1.19M as of Q2 2026.
  • Virtus Investment Advisers sold 98,743 Iovance Biotherapeutics shares in Q2 2026, an estimated $375K.
  • Iovance Biotherapeutics made up 0.28% of Virtus Investment Advisers's portfolio in Q2 2026, its #182 holding.
  • Virtus Investment Advisers first reported a position in Iovance Biotherapeutics in Q1 2025 and has held it in 6 quarters since.
  • Virtus Investment Advisers's Iovance Biotherapeutics position peaked at $1.35M in Q1 2026.
  • 292 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q2 2026.

Based on Virtus Investment Advisers's 13F filing for Q2 2026, filed 11 Aug 2026.